Masuda Elna M, Kessler Darcy M, Lurie Fedor, Puggioni Alessandra, Kistner Robert L, Eklof Bo
Straub Clinic & Hospital, Honolulu, HI 96813, USA.
J Vasc Surg. 2006 Mar;43(3):551-6; discussion 556-7. doi: 10.1016/j.jvs.2005.11.038.
Current techniques to treat venous ulcerations and patients with severe lipodermatosclerosis include the elimination of incompetent perforator veins by open surgical ligation and division or by subfascial endoscopic perforator surgery. An alternative and less invasive means to obliterate perforator veins is ultrasound-guided sclerotherapy (UGS). We hypothesize that UGS is a clinically effective means of eliminating perforator veins and results in improvement of the clinical state (scores) without the complications associated with other more invasive methods.
Between January 2000 and March 2004, UGS was used to treat chronic venous insufficiency in 80 limbs of 68 patients. This was a clinical series of patients who had perforator incompetence and no previous surgery for venous disease < or = 2 years of their UGS procedure. Most had perforator disease without coexisting axial reflux of the saphenous or deep venous systems. Color flow duplex scanning was used to identify incompetent perforator veins in the calf, and duplex guidance was used to inject each perforator with the liquid sclerosant sodium morrhuate (5%). Patients were restudied by duplex scanning up to 5 years after treatment. Clinical results were determined by Venous Clinical Severity Score (VCSS) and Venous Disability Score (VDS) before and after treatment.
Of the 80 limbs treated with UGS, 98% of incompetent perforators were successfully obliterated at the time of treatment, and 75% of limbs showed persistent occlusion of perforators and remained clinically improved with a mean follow-up of 20.1 months. According to the CEAP classification, there were 46.2% with limb ulceration or C6, 1.2% C5, 28.7% C4, 17.5% C3, and 6.2% C2 with pain isolated to the site of the perforator(s). Of those who returned for follow-up, the VCSSs changed from a median of 8 before treatment (95% confidence interval [CI], 3 to 15) to a median of 2 after treatment (95% CI, 0 to 7) (P < .01). Likewise, VDSs dropped from a median of 4 before treatment (95% CI, 1 to 3) to 1 after treatment (95% CI, 0 to 2) (P < .01). There were no cases of deep vein thrombosis involving the deep vein adjacent to the perforator injected. One patient had skin complications with skin necrosis. Perforator recurrence was found more frequently in those with ulcerations than those without.
UGS is an effective and durable method of eliminating incompetent perforator veins and results in significant reduction of symptoms and signs as determined by venous clinical scores. As an alternative to open interruption or subfascial endoscopic perforator surgery, UGS may lead to fewer skin and wound healing complications. Perforator recurrence occurs particularly in those with ulcerations, and therefore, surveillance duplex scanning after UGS and repeat injections may be needed.
目前治疗静脉溃疡和重度脂肪硬化性皮炎患者的技术包括通过开放手术结扎和切断或通过筋膜下内镜下穿支静脉手术来消除功能不全的穿支静脉。一种替代的、侵入性较小的闭塞穿支静脉的方法是超声引导下硬化疗法(UGS)。我们推测UGS是一种消除穿支静脉的临床有效方法,可改善临床状况(评分),且无其他侵入性更强方法所伴随的并发症。
2000年1月至2004年3月期间,UGS被用于治疗68例患者的80条肢体的慢性静脉功能不全。这是一组临床病例,这些患者存在穿支静脉功能不全,且在接受UGS治疗前2年或更短时间内未接受过静脉疾病手术。大多数患者有穿支静脉疾病,且大隐静脉或深静脉系统无并存的轴性反流。彩色血流双功扫描用于识别小腿部功能不全的穿支静脉,并用双功超声引导向每条穿支静脉注射液体硬化剂鱼肝油酸钠(5%)。治疗后长达5年对患者进行双功扫描复查。治疗前后通过静脉临床严重程度评分(VCSS)和静脉残疾评分(VDS)来确定临床结果。
在接受UGS治疗的80条肢体中,98%的功能不全穿支静脉在治疗时成功闭塞,75%的肢体穿支静脉持续闭塞,平均随访20.1个月时临床状况仍有改善。根据CEAP分类,46.2%的患者有肢体溃疡或C6级,1.2%为C5级,28.7%为C4级,17.5%为C3级,6.2%为C2级,疼痛仅局限于穿支静脉部位。在接受随访的患者中,VCSS从治疗前的中位数8(95%置信区间[CI],3至15)降至治疗后的中位数2(95%CI,0至7)(P <.01)。同样,VDS从治疗前的中位数4(95%CI,1至3)降至治疗后的1(95%CI,0至2)(P <.01)。未发生涉及注射穿支静脉相邻深静脉的深静脉血栓形成病例。1例患者出现皮肤坏死等皮肤并发症。溃疡患者的穿支静脉复发比无溃疡患者更常见。
UGS是一种有效且持久的消除功能不全穿支静脉的方法,可使静脉临床评分所确定的症状和体征显著减轻。作为开放手术切断或筋膜下内镜下穿支静脉手术的替代方法,UGS可能导致更少的皮肤和伤口愈合并发症。穿支静脉复发尤其发生在溃疡患者中,因此,UGS后可能需要进行双功超声监测并重复注射。